Dr Reddy’s Debuts Daraprim Rival In US
Also Introduces Naloxone With CGT Exclusivity And First Generic Ziprasidone
Dr Reddy’s has launched the first generic version of Daraprim in the US. The company has also introduced naloxone with 180 days of exclusivity under the FDA’s Competitive Generic Therapy pathway, as well as the first US generic of ziprasidone mesylate.
You may also be interested in...
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.
Teva has received FDA approval for the first US generic naloxone nasal spray after a 30-month stay linked to ongoing patent litigation expired. Launch plans have not yet been revealed. Meanwhile, the Israeli firm has also introduced the first generic version of VESIcare in the US.
Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.